drugset / Trial / NCT04749563
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
RandomizedSequentialTriple-blindTreatment
Summary
A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).
Timeline
- Start
- 2021-01-11
- Primary completion
- 2021-06-20
- Completion
- 2021-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IGC AD1 | Unknown | — | Oral |